Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Dent

Showing results (51-60 of 395) with videos related to

Pageof 40
Sort By:
Blood|January 11, 2003
Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cellsShujie Wang, Zhiliang Wang, Paul Dent, et al.
Molecular Pharmacology|June 28, 2007
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulationMohamed Rahmani, Tri K Nguyen, Paul Dent, et al.
Cancer Biology & Therapy|August 17, 2017
[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy|August 25, 2018
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibodyLaurence Booth, Jane Lisa Roberts, Andrew Poklepovic, et al.
Cellular Signalling|September 15, 2019
Signaling alterations caused by drugs and autophagyPaul Dent, Laurence Booth, Andrew Poklepovic, et al.
Cellular Signalling|February 23, 2020
The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cellsJane L Roberts, Andrew Poklepovic, Laurence Booth, et al.
Frontiers in Oncology|September 28, 2020
GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Anti-Cancer Drugs|March 11, 2022
Mechanisms of GZ17-6.02 resistanceLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Leukemia Research|May 14, 2019
Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]Girija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Frontiers in Oncology|May 3, 2021
Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells <i>via</i> Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Pageof 40

Showing results (51-60 of 395) with videos related to

Sort By:
Pageof 40
Blood|January 11, 2003
Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cellsShujie Wang, Zhiliang Wang, Paul Dent, et al.
Molecular Pharmacology|June 28, 2007
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulationMohamed Rahmani, Tri K Nguyen, Paul Dent, et al.
Cancer Biology & Therapy|August 17, 2017
[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy|August 25, 2018
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibodyLaurence Booth, Jane Lisa Roberts, Andrew Poklepovic, et al.
Cellular Signalling|September 15, 2019
Signaling alterations caused by drugs and autophagyPaul Dent, Laurence Booth, Andrew Poklepovic, et al.
Cellular Signalling|February 23, 2020
The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cellsJane L Roberts, Andrew Poklepovic, Laurence Booth, et al.
Frontiers in Oncology|September 28, 2020
GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Anti-Cancer Drugs|March 11, 2022
Mechanisms of GZ17-6.02 resistanceLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Leukemia Research|May 14, 2019
Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]Girija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Frontiers in Oncology|May 3, 2021
Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells <i>via</i> Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Pageof 40